Top Markets
Coin of the day
CMIC HOLDINGS Co., Ltd. CMIC HOLDINGS Co., Ltd.

CMIC HOLDINGS Co., Ltd.

2309
Clasificación en acciones #16496
Based in Tokyo, Japan, CMIC HOLDINGS Co., Ltd. serves as a leading provider of... Based in Tokyo, Japan, CMIC HOLDINGS Co., Ltd. serves as a leading provider of extensive services to the pharmaceutical industry within Japan. Its operational framework is structured across five strategic segments: Contract Research Organization (CRO), Contract Development and Manufacturing Organization (CDMO), Contract Sales Organization (CSO), Healthcare, and Innovative Pharma Model. Through its CRO capabilities, the company orchestrates comprehensive clinical trial services, encompassing everything from clinical operations, precise data management, and medical writing to patient recruitment, pharmacovigilance, project leadership, and stringent audit and quality assurance, alongside expert statistical analysis. Additionally, it offers critical consulting expertise in areas like clinical site network development, drug formulation, health economics, market entry strategies, and regulatory navigation, including advice on national health insurance pricing for medical devices and in vitro diagnostics. CMIC's CDMO division is instrumental in drug development and manufacturing, handling commercial supply, contract development, investigational product manufacturing, and specialized tasks such as packaging, labeling, release and stability testing, and technology transfer, bolstered by advanced formulation, process, and analytical development services. The company also operates sophisticated laboratory facilities, delivering bioanalysis, GLP/GMP analysis, and studies on biomarkers, large and small molecules, oligonucleotides, and conducting thorough toxicity, safety pharmacology, and non-clinical assessments. Within its Healthcare segment, CMIC focuses on patient and healthcare support, offering innovative solutions like drug adherence programs, specialized health platforms (harmo, Helc+), extensive prescription drug databases, and personalized health checks (selcheck). Beyond these, its portfolio includes post-marketing surveillance, self-inspection, regulatory affairs consulting, regulatory submissions and correspondence, sales and marketing support, and efficient clinical research coordinating and site management services. Demonstrating its commitment to innovation, CMIC HOLDINGS Co., Ltd. has entered into a strategic partnership with Science 37, Inc. to advance the adoption of decentralized clinical trials, thereby accelerating the progress of new treatment development. The company was originally established in 1985.
Precio por acción
$17.25
Última sincronización: 2024-03-27
Capitalización bursátil
$291.27M
Cambio (1 día)
-0.46%
Cambio (1 año)
0.00%
País
JP
Comercio CMIC HOLDINGS Co., Ltd. (2309)

Categoría

Ratio P/E de CMIC HOLDINGS Co., Ltd. (2309)
Ratio P/E al 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de CMIC HOLDINGS Co., Ltd., el P/E actual (TTM) de la empresa es 0. Al final de 2026, la empresa tenía un P/E de 0.
Historial del ratio P/E de CMIC HOLDINGS Co., Ltd. desde 2026 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
Not enough data for the provided dates.
Relación P/E para empresas similares o competidores
Empresa P/E Ratio Diferencia del P/E Ratio País
33.14 -
US
37.80 -
US
- -
CN
-236.74 -
US
39.09 -
US
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.